Problemas Oculares

Astragalus (Huang Qi) is one of the most frequently used herbs in clinical TCM trials for COPD. A 2023 systematic review and meta-analysis found that astragalus injection combined with ambroxol hydrochloride significantly improved COPD outcomes. Its anti-inflammatory and antioxidant actions reduce oxidative stress in lung tissue. Astragalus appears in both stable COPD and acute exacerbation studies.

Baicalin is a flavonoid glycoside from Scutellaria baicalensis (Chinese skullcap), extensively studied in COPD preclinical models. It attenuates airway inflammation by inhibiting NF-κB activation and reducing TNF-α, IL-6, and IL-8. In cigarette smoke/LPS mouse models, baicalin improved lung function and reduced inflammatory cell infiltration. It is recognized in a 2023 PMC review as having therapeutic potential across multiple lung diseases including COPD.

Patients with COPD have significantly lower skeletal muscle carnosine levels and suffer from elevated exercise-induced acidosis and oxidative stress, creating a mechanistic rationale for BA supplementation. A 12-week double-blind RCT (n=40, 3.2 g/day) confirmed that BA significantly increases muscle carnosine in COPD patients, though improvements in exercise capacity and quadriceps function did not reach statistical significance in this stable cohort. Ongoing larger trials (BASE-TRAIN, BASE-ELECTRIC; n=222) are testing BA as an adjunct to pulmonary rehabilitation.

Cordyceps sinensis (CS) is a traditional Chinese medicinal fungus with substantial clinical data in COPD. A 2019 systematic review and meta-analysis of 15 RCTs (n=1,238 participants) found CS preparations improved lung function, exercise endurance, quality of life, and symptoms in GOLD stage 2–3 stable COPD patients. Evidence quality is limited by lack of placebo controls in many included studies.

Curcumin, the primary bioactive polyphenol in turmeric, has been evaluated in COPD RCTs. A 2025 systematic review and meta-analysis found curcumin (200–500 mg/day) significantly reduced systolic blood pressure and improved FEV1 (SMD=−0.82) compared to placebo in COPD patients. It is recommended as an adjuvant option in this review. Bioavailability is low without enhanced formulations.

DHA is an omega-3 fatty acid showing particularly strong associations with lung function preservation in COPD. A large longitudinal study (n>15,000) found that higher DHA concentrations were specifically associated with improved lung capacity over time. DHA is metabolized to protectins and resolvins that help resolve airway inflammation.

EPA is an omega-3 fatty acid whose serum levels are inversely associated with inflammatory markers (TNF-α) in stable COPD. An RCT in 86 COPD patients showed that combined omega-3/vitamin D/leucine supplementation improved serum EPA levels alongside exercise tolerance. A PMC review identifies EPA among micronutrients protective against COPD progression.

Multiple clinical trials support oral 1,8-cineole (eucalyptol) as an adjunct therapy in COPD, reducing exacerbation frequency and improving lung function. A 6-month, double-blind, placebo-controlled multicenter RCT found significant reductions in exacerbation severity and duration versus placebo. Enteric-coated eucalyptol capsules are approved in Germany for adjunctive inflammatory respiratory treatment.

Multiple animal studies demonstrate Fritillaria alkaloids improve lung function and suppress COPD-relevant inflammation. Imperialine mitigated pulmonary impairment in a cigarette smoke/LPS COPD rat model. A total alkaloid extract from B. Fritillariae pallidiflorae improved pulmonary function, histopathology, and oxidative stress markers in cigarette smoke-induced COPD mice.

Panax ginseng has been used in traditional Chinese medicine for respiratory conditions for millennia and has documented preclinical and early clinical evidence in COPD. Korean Red Ginseng extract and ginsenosides inhibit MAPK/NF-κB/c-Fos inflammatory pathways in lung models. Multiple small controlled clinical trials showed promising effects on COPD symptoms and quality of life, prompting a registered RCT (RMIT University/Austin Hospital).

Ginsenosides, the main active components of Panax ginseng, have demonstrated anti-inflammatory activity via MAPK/NF-κB inhibition in preclinical lung models relevant to COPD. A 2023 PubMed review confirmed their potential in improving COPD, asthma, and pulmonary fibrosis. Korean Red Ginseng-derived ginsenosides have been studied at 6 g/day for COPD-related lung inflammation.

NAC (which converts to L-cysteine in the body) is a proven adjunctive therapy for COPD, reducing exacerbation frequency, improving small airway function, and decreasing airway oxidative stress. Meta-analyses of multiple RCTs consistently show significantly fewer COPD exacerbations with NAC. High-dose NAC (600 mg twice daily) is required for clinical benefit.

GSH levels are depleted in COPD lung tissue and secretions, and oxidative stress is a central disease mechanism. A cohort study in 50 COPD patients found sublingual GSH (300 mg twice daily) alongside standard therapy increased antioxidant enzymes SOD3 and GPX1, though reductions in inflammatory markers IL-8 and TNF-α did not reach statistical significance versus the control group. GSH-S-transferase omega is altered in COPD lung tissue.

Luteolin reduces pulmonary inflammation, oxidative stress, and alveolar damage in COPD preclinical models through NF-κB, Nrf2/HO-1, and MAPK pathway modulation. It is consistently identified as a candidate for COPD management in systematic reviews.

Magnesium deficiency is common in COPD patients. A 2024 systematic review found magnesium supplementation may reduce inflammation levels in COPD patients. Intravenous magnesium sulfate is used in severe acute exacerbations for its bronchodilatory effect. A broad PMC review lists magnesium among micronutrients protective against chronic lung disease.

Adhatoda vasica is documented in pharmacological reviews as having multi-target mechanisms relevant to COPD, including bronchodilatory, anti-inflammatory, and mucolytic activity. Recent 2022–2025 research has specifically highlighted COPD among its mechanistic targets. Traditional use includes chronic bronchitis, the main component of COPD.

NAC is a mucolytic and antioxidant agent extensively studied in COPD. It acts as a glutathione precursor, reducing oxidative stress and mucus viscosity. Multiple meta-analyses and RCTs show high-dose NAC (600 mg twice daily) reduces exacerbation frequency and improves small airway function in stable COPD patients. Evidence is mixed at low doses.

Omega-3 fatty acids (EPA and DHA) have documented anti-inflammatory properties relevant to COPD. A large longitudinal study (n>15,000) found higher omega-3 concentrations were associated with slower lung function decline. Clinical trials in COPD show omega-3 improves muscle health and protein balance. An authoritative PMC review identifies omega-3 fatty acids as protective against COPD progression.

Platycodon has been studied in cigarette smoke-induced chronic bronchitis models relevant to COPD pathology. PG inhibits TLR4/MyD88/NF-κB-driven airway inflammation and reduces mucus hypersecretion and structural airway changes. Evidence is from preclinical studies; no human COPD trials exist.

Quercetin is a dietary flavonoid under clinical investigation for COPD. Preclinical studies show it prevents progression of COPD-like lung disease in mice by inhibiting MMP expression and rhinovirus replication. A safety RCT (BMJ Open Respiratory Research, 2020) established its tolerability in COPD patients. Phase II efficacy trials are ongoing. Definitive clinical efficacy has not yet been established.

Resveratrol is a polyphenol evaluated in COPD for its anti-inflammatory and mitochondrial effects. A 2025 meta-analysis found resveratrol significantly downregulated serum TNF-α and IL-8 in COPD patients. The CARMENS trial (Maastricht University Medical Center) investigated resveratrol's effect on mitochondrial function in COPD. Preclinical rat models also show antioxidant and anti-inflammatory activity in cigarette smoke-induced COPD models.

Rhodiola crenulata (RC) was evaluated in a 12-week randomized double-blind placebo-controlled trial (n=57 stable moderate-to-severe COPD patients). RC 250 mg twice daily significantly improved workload capacity (Δ=+10%, p=0.01) and attenuated FEV1 decline (4.5%, p=0.03) compared to placebo. Salidroside from Rhodiola also demonstrated efficacy in a 2025 COPD polyphenol meta-analysis.

Salidroside, the primary active phenylpropanoid glycoside of Rhodiola, was shown in a 2025 systematic review and meta-analysis of COPD polyphenol RCTs to reduce thrombotic markers (TT, D-D), inflammatory factors (TNF-α), and symptom scores (CAT) (p<0.01) compared to placebo. It was identified as one of only two polyphenols (with curcumin) showing clear efficacy in this meta-analysis.

Selenium is an essential trace element critical for glutathione peroxidase activity, a key antioxidant enzyme in COPD airways. Multiple authoritative reviews identify selenium deficiency as a risk factor for COPD progression. A PMC review of vitamins, minerals, and antioxidants in COPD specifically lists selenium as protective against chronic lung disease. Dietary selenium intake is inversely associated with COPD risk in epidemiological studies.

SPM deficiency has been documented in COPD patients, with evidence of impaired resolution mechanisms contributing to persistent airway inflammation. SPMs attenuate serum amyloid A-driven inflammation and normalize cytokine/chemokine imbalances in COPD models. Reduced LXA4 and other SPM levels have been confirmed in human COPD tissue and sputum samples.

Sulforaphane suppresses TLR2/4-mediated pro-inflammatory cytokine release in macrophages isolated from COPD patients, suggesting therapeutic potential. However, clinical RCTs to date have not shown significant improvements in pulmonary function or systemic inflammation markers in COPD patients.

Tanshinone (from Danshen/Salvia miltiorrhiza) is recommended as an adjuvant treatment option for COPD in a 2025 systematic review and meta-analysis of polyphenol RCTs. Tanshinones are diterpenoid quinones with demonstrated anti-inflammatory and anticoagulant effects in COPD patients, improving coagulation markers and inflammatory cytokines.

Theophylline is a methylxanthine bronchodilator with over 70 years of use in COPD. It inhibits phosphodiesterase (PDE3/4), relaxes airway smooth muscle, and has anti-inflammatory effects including neutrophil suppression in induced sputum. GOLD guidelines permit it only when other bronchodilators are unavailable or unaffordable. Evidence on exacerbation reduction is limited and contradictory.

Vitamin C is a primary antioxidant studied in COPD. A systematic review and meta-analysis specifically on vitamin C supplementation in COPD (PMC, 2022) found it can promote lung function and serum antioxidant levels by decreasing oxidative damage. However, supplementation alone did not show significant effects on FEV1 in a broader 2024 meta-analysis. Its antioxidant role in COPD pathophysiology is well-established.

Vitamin D deficiency is prevalent in COPD patients and linked to increased exacerbation risk and impaired immune function. A systematic review and meta-analysis found vitamin D supplementation alone improved lung function (FEV1, FEV1/FVC) in COPD patients. An RCT in 120 COPD patients showed clinical improvement with calcitriol. Multiple authoritative reviews support vitamin D as protective against COPD progression.

Vitamin D3 (cholecalciferol) is the directly studied form of vitamin D in COPD RCTs. An RCT in 120 COPD patients compared 50,000 IU/day vitamin D3 against calcitriol and placebo, finding clinical improvement in treated groups. A 2024 systematic review confirmed vitamin D3 supplementation improved FEV1 in COPD patients. Deficiency of D3 is strongly associated with increased exacerbation risk.

Vitamin E (primarily alpha-tocopherol) is a fat-soluble antioxidant studied in COPD. A PMC review identifies vitamin E among antioxidants that may protect against COPD progression. A 2024 meta-analysis found vitamin E alone did not significantly improve lung function in COPD, but it contributes to synergistic antioxidant effects with vitamin C in combination. Dietary vitamin E intake is inversely correlated with COPD risk in observational studies.

Zinc deficiency is prevalent in COPD patients and contributes to impaired antioxidant defense and immune function. A PMC review lists zinc among micronutrients with protective roles against chronic lung disease. A 2024 meta-analysis includes zinc in complex micronutrient supplementation that improved FEV1 and FEV1/FVC in COPD patients.

TCM literature documents Aster root for chronic cough, wheezing, and lung deficiency—conditions that overlap clinically with COPD. Modern pharmacological studies on airway inflammation mechanisms are relevant to COPD pathophysiology, though no research has directly studied COPD patients or COPD animal models with Aster root.

Coltsfoot has documented traditional use for chronic obstructive lung conditions including emphysema and silicosis—conditions with overlapping pathophysiology to COPD. It is described in herbal traditions as useful for chronic debilitating lung conditions with persistent cough and trapped mucus. No clinical trials exist.

Echinacea is identified in authoritative herbal sources (Herbal Reality) as a strong antimicrobial herb with a role in acute COPD exacerbations and chronic bronchitis, used to reduce infection-triggered flares. It is widely used in Western herbal medicine for respiratory infections. The German Commission E and ESCOP have approved Echinacea preparations for upper respiratory tract infections, which are a primary trigger for COPD exacerbations.

Elecampane (Inula helenium) has a documented traditional use in COPD, chronic bronchitis, and emphysema. It contains alantolactone and inulin, which stimulate expulsion of thick sticky mucus—vital in COPD where mucus accumulation impairs breathing. Herbal Reality, an authoritative herbalism source, specifically identifies elecampane for COPD and chronic bronchitis.

Garlic is identified by authoritative herbal sources (Herbal Reality) as a strong antimicrobial herb used in acute COPD exacerbations and chronic bronchitis to address infection triggers. Its active constituents allicin and related organosulfur compounds have documented antimicrobial, anti-inflammatory, and expectorant properties. Traditional use in respiratory conditions is long-established across multiple cultures.

Ginger (Zingiber officinale) is identified in authoritative herbal sources (Herbal Reality) as a circulatory stimulant and potent anti-inflammatory that can potentiate expectorants and help reduce airway inflammation in COPD. It has a long history in TCM and Ayurvedic medicine for respiratory conditions. Preclinical evidence supports anti-inflammatory effects on airway tissue.

A PubMed-indexed ethnopharmacological review (2022) documented that I. racemosa has a potential to treat respiratory tract infections including COPD. This is based on traditional documentation and pharmacological plausibility rather than clinical trial data. The plant's expectorant, bronchodilator, and anti-inflammatory properties are the mechanistic basis.

Licorice root (Glycyrrhiza spp.) is one of the eight most frequently used herbs in clinical TCM trials for both stable COPD and acute COPD exacerbations, per a systematic review of 176 TCM clinical trials. It is a demulcent expectorant used in Western herbalism for dry, irritable cough and asthma. Glycyrrhizin and glycyrrhizinic acid have documented anti-inflammatory and antiviral properties.

Lobelia (Lobelia inflata) is a traditional respiratory stimulant and bronchodilator used in Western herbal medicine for COPD, emphysema, and asthma. Herbal Reality identifies it as a powerful bronchodilator that eases breathing and clears mucus. Its active alkaloid lobeline has bronchodilatory properties. It is a Schedule 20 herb in the UK, requiring practitioner prescription due to potency.

Marshmallow root (Althaea officinalis) is classified as a demulcent expectorant by Herbal Reality specifically for COPD, listed alongside liquorice, plantain, and mullein for dry, non-productive, irritable cough in asthma and COPD. Rich in mucilage, it soothes inflamed mucosal surfaces in the respiratory tract. The European Medicines Agency (EMA) supports marshmallow root for irritation of oral and pharyngeal mucosa.

Mullein (Verbascum thapsus) has been used for centuries as a traditional expectorant and respiratory tonic for bronchitis, emphysema, and COPD-like conditions. It is recognized by herbalists as a stimulative expectorant that loosens thick mucus. Authoritative herbal resources including Herbal Reality identify mullein for COPD/emphysema support, though clinical RCT evidence is absent.

Yuan Zhi has been used in TCM as an expectorant and anti-inflammatory herb relevant to obstructive pulmonary disease. A 2025 preclinical study examined PT water extract in a cigarette smoke-induced COPD mouse model, finding improved lung function and reduced inflammation. No human COPD trials have been published.

A 2025 Frontiers in Microbiology/PMC study specifically investigated Polygala tenuifolia water extract in a COPD animal model, finding anti-inflammatory effects and microbiome/lung epithelial benefits. The Chinese Pharmacopoeia lists anti-asthmatic applications. Human COPD trials are lacking.

Thyme (Thymus vulgaris) is a well-established traditional remedy for spasmodic cough, bronchitis, and chronic airway conditions including COPD. Herbal Reality identifies it as a warming expectorant and strong antimicrobial herb with a role in acute COPD exacerbations. Its active constituent thymol has documented mucolytic and antispasmodic properties. The German Commission E has approved thyme leaf for bronchitis.